Eagle Pharmaceuticals, Inc. (EGRX)
OTCMKTS · Delayed Price · Currency is USD
1.600
-1.400 (-46.67%)
Oct 9, 2025, 3:53 PM EDT
Eagle Pharmaceuticals Revenue
Eagle Pharmaceuticals had revenue of $64.65M in the quarter ending June 30, 2023, a decrease of -12.80%. This brings the company's revenue in the last twelve months to $257.55M, down -5.38% year-over-year. In the year 2022, Eagle Pharmaceuticals had annual revenue of $316.61M with 84.56% growth.
Revenue (ttm)
257.55M
Revenue Growth
-5.38%
P/S Ratio
0.08
Revenue / Employee
1.92M
Employees
134
Market Cap
20.84M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 316.61M | 145.06M | 84.56% |
Dec 31, 2021 | 171.55M | -16.26M | -8.66% |
Dec 31, 2020 | 187.80M | -8.09M | -4.13% |
Dec 31, 2019 | 195.89M | -17.42M | -8.17% |
Dec 31, 2018 | 213.31M | -23.40M | -9.88% |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Elite Pharmaceuticals | 105.45M |
Glass House Brands | 221.55M |
Veradigm | 588.02M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Jushi Holdings | 256.36M |
Nuo Therapeutics | 1.95M |
Eagle Pharmaceuticals News
- 3 days ago - Eagle Pharmaceuticals GAAP EPS of -$3.88, revenue of $37.27M - Seeking Alpha
- 3 days ago - Eagle Pharmaceuticals Announces Availability of Unaudited First Quarter 2025 Financial Statements - GlobeNewsWire
- 22 days ago - Eagle Pharmaceuticals Announces Availability of Proxy Materials and Audited Financial Statements for the 2023 and 2024 Fiscal Years - GlobeNewsWire
- 6 weeks ago - Eagle Pharmaceuticals to Appoint Abhinav Jain to its Board of Directors - GlobeNewsWire
- 7 weeks ago - Eagle Pharmaceuticals Announces 2025 Annual Meeting Date - GlobeNewsWire
- 6 months ago - Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties - Benzinga
- 7 months ago - Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan - GlobeNewsWire
- 8 months ago - Nantahala Capital Management, LLC Acquires Significant Stake in Eagle Pharmaceuticals Inc - GuruFocus